These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 25879879

  • 1. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA.
    Arthritis Res Ther; 2015 Mar 19; 17(1):66. PubMed ID: 25879879
    [Abstract] [Full Text] [Related]

  • 2. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr 19; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies.
    Guyot P, Pandhi S, Nixon RM, Iqbal A, Chaves RL, Andrew Moore R.
    Scand J Pain; 2017 Jul 19; 16():74-88. PubMed ID: 28850416
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 19; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018 Aug 19; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 7. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ, Figgitt DP.
    Drugs; 2001 Nov 18; 61(6):833-65. PubMed ID: 11398914
    [Abstract] [Full Text] [Related]

  • 8. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S, Klotz U.
    Eur J Clin Pharmacol; 2008 Mar 18; 64(3):233-52. PubMed ID: 17999057
    [Abstract] [Full Text] [Related]

  • 9. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B, Berenbaum F.
    Expert Opin Investig Drugs; 2005 Apr 18; 14(4):521-33. PubMed ID: 15882125
    [Abstract] [Full Text] [Related]

  • 10. Celecoxib clinical profile.
    Tive L.
    Rheumatology (Oxford); 2000 Dec 18; 39 Suppl 2():21-8; discussion 57-9. PubMed ID: 11276798
    [Abstract] [Full Text] [Related]

  • 11. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC.
    Semin Arthritis Rheum; 2002 Dec 18; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [Abstract] [Full Text] [Related]

  • 12. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
    Niculescu L, Li C, Huang J, Mallen S.
    Curr Med Res Opin; 2009 Mar 18; 25(3):729-40. PubMed ID: 19210159
    [Abstract] [Full Text] [Related]

  • 13. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 18; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
    Lister BJ, Poland M, DeLapp RE.
    Am J Med; 1993 Aug 09; 95(2A):2S-9S. PubMed ID: 8356999
    [Abstract] [Full Text] [Related]

  • 15. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L, Goldstein JL, Vu A, Mayne TJ, Rublee DA.
    Am J Gastroenterol; 2005 May 09; 100(5):1043-50. PubMed ID: 15842577
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ, Smith LA, Bradley MD.
    BMJ; 2002 Sep 21; 325(7365):619. PubMed ID: 12242171
    [Abstract] [Full Text] [Related]

  • 17. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
    Solomon DH, Husni ME, Wolski KE, Wisniewski LM, Borer JS, Graham DY, Libby P, Lincoff AM, Lüscher TF, Menon V, Yeomans ND, Wang Q, Bao W, Berger MF, Nissen SE, PRECISION Trial Investigators.
    Arthritis Rheumatol; 2018 Apr 21; 70(4):537-546. PubMed ID: 29266879
    [Abstract] [Full Text] [Related]

  • 18. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
    Curr Med Res Opin; 2006 Dec 21; 22(12):2365-74. PubMed ID: 17265571
    [Abstract] [Full Text] [Related]

  • 19. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 21; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
    Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG, National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.
    BMJ; 2009 Jul 14; 339():b2538. PubMed ID: 19602530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.